These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 9350673)

  • 21. An oral adsorbent, AST-120, combined with a low-protein diet and RAS blocker, for chronic kidney disease.
    Yorioka N; Kiribayashi K; Naito T; Ogata S; Yokoyama Y; Kyuden Y; Ogawa T; Wada K; Hayashi K; Hirabayashi A
    J Nephrol; 2008; 21(2):213-20. PubMed ID: 18446716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic effects of long-term administration of an oral adsorbent in patients with chronic renal failure: two-year study.
    Takahashi N; Kawaguchi T; Suzuki T
    Int J Urol; 2005 Jan; 12(1):7-11. PubMed ID: 15661048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indoxyl sulfate is a nephro-vascular toxin.
    Niwa T
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S2-6. PubMed ID: 20797565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease.
    Fujii H; Nakai K; Fukagawa M
    Ther Apher Dial; 2011 Apr; 15(2):125-8. PubMed ID: 21426501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An oral adsorbent ameliorates renal overload of indoxyl sulfate and progression of renal failure in diabetic rats.
    Aoyama I; Niwa T
    Am J Kidney Dis; 2001 Jan; 37(1 Suppl 2):S7-S12. PubMed ID: 11158853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral adsorbent AST-120 ameliorates tubular injury in chronic renal failure patients by reducing proteinuria and oxidative stress generation.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Suzuki T; Ueda Y; Yamagishi S
    Metabolism; 2011 Feb; 60(2):260-4. PubMed ID: 20189611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory effect of oral sorbent on accumulation of albumin-bound indoxyl sulfate in serum of experimental uremic rats.
    Niwa T; Yazawa T; Ise M; Sugano M; Kodama T; Uehara Y; Maeda K
    Nephron; 1991; 57(1):84-8. PubMed ID: 1904558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats.
    Niwa T; Miyazaki T; Hashimoto N; Hayashi H; Ise M; Uehara Y; Maeda K
    Am J Nephrol; 1992; 12(4):201-6. PubMed ID: 1481866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of AST-120 on blood concentrations of protein-bound uremic toxins and biomarkers of cardiovascular risk in chronic dialysis patients.
    Lee CT; Hsu CY; Tain YL; Ng HY; Cheng BC; Yang CC; Wu CH; Chiou TT; Lee YT; Liao SC
    Blood Purif; 2014; 37(1):76-83. PubMed ID: 24576840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of repeated oral administrations of the oral adsorbent AST-120 on serum creatinine and other markers of renal function. A randomized controlled study in patients with chronic kidney disease.
    Marier JF; Lee J; Kambhampati SR; Galitz L; Vargas R; Moberly J; Salazar DE
    Am J Nephrol; 2006; 26(2):136-41. PubMed ID: 16549905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD.
    Schulman G; Agarwal R; Acharya M; Berl T; Blumenthal S; Kopyt N
    Am J Kidney Dis; 2006 Apr; 47(4):565-77. PubMed ID: 16564934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An oral sorbent, AST-120, increases Klotho expression and inhibits cell senescence in the kidney of uremic rats.
    Adijiang A; Niwa T
    Am J Nephrol; 2010; 31(2):160-4. PubMed ID: 19955715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats.
    Iwasaki Y; Yamato H; Nii-Kono T; Fujieda A; Uchida M; Hosokawa A; Motojima M; Fukagawa M
    Nephrol Dial Transplant; 2006 Oct; 21(10):2768-74. PubMed ID: 16820376
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure.
    Nakamura T; Kawagoe Y; Matsuda T; Ueda Y; Shimada N; Ebihara I; Koide H
    Kidney Blood Press Res; 2004; 27(2):121-6. PubMed ID: 15051932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGF-beta1 in uraemic rat kidneys.
    Miyazaki T; Aoyama I; Ise M; Seo H; Niwa T
    Nephrol Dial Transplant; 2000 Nov; 15(11):1773-81. PubMed ID: 11071964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of oral adsorbent AST-120 under standard treatment of care in patients with chronic renal failure].
    Yoshida I; Komada T; Sakuma Y; Mori H; Funayama I; Tabei K
    Nihon Jinzo Gakkai Shi; 2009; 51(2):121-9. PubMed ID: 19378798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum indoxyl sulfate levels in patients with diabetic nephropathy: relation to renal function.
    Atoh K; Itoh H; Haneda M
    Diabetes Res Clin Pract; 2009 Feb; 83(2):220-6. PubMed ID: 19027976
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
    Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uremic toxins and oral adsorbents.
    Goto S; Yoshiya K; Kita T; Fujii H; Fukagawa M
    Ther Apher Dial; 2011 Apr; 15(2):132-4. PubMed ID: 21426503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Serum indoxyl sulfate is a useful predictor for progression of chronic kidney disease].
    Namba S; Okuda Y; Morimoto A; Kojima T; Morita T
    Rinsho Byori; 2010 May; 58(5):448-53. PubMed ID: 20560454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.